Robert Hettle
136 Hills Road
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Cure Models: What is Meant by a Survival 'Plateau', and Do Experts Agree on What Constitutes One?
Journal: PharmacoEconomics
Published: May 17, 2025
'Twenty years of network meta-analysis: Continuing controversies and recent developments': A health technology assessment perspective.
Journal: Research synthesis methods
Published: April 23, 2024
Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Journal: PharmacoEconomics - open
Published: November 19, 2023
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Journal: Expert review of anticancer therapy
Published: October 18, 2023
New Methods for Two-Stage Treatment Switching Estimation.
Journal: Pharmaceutical statistics
Published: October 09, 2023
Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review.
Journal: Future oncology (London, England)
Published: September 08, 2023
Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Journal: Medical decision making : an international journal of the Society for Medical Decision Making
Published: July 14, 2023
A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
Journal: American journal of hematology
Published: May 26, 2023
Author response to 'Comment on "Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer" (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)'.
Journal: Therapeutic advances in medical oncology
Published: April 28, 2023
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal: Targeted oncology
Published: August 20, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 09, 2021
Last Updated: 09/26/2026